Newsletter | April 10, 2026

04.10.26 -- Ever Wonder What Running A $50B Capital Facilities Project Feels Like?

SPONSOR

7th Supply Chain & Logistics for Cell & Gene Therapy Summit

The 7th Supply Chain & Logistics for Cell & Gene Therapy Summit, June 9–11, 2026 in Washington, D.C., unites 75+ CGT supply chain, logistics, and patient operations leaders to tackle global delivery challenges. Explore digitalization, AI, COI/COC, scaling, and regulatory navigation through case studies and expert insights. Build the resilient, future ready supply chain advanced therapies demand.

FOCUS ON SUPPLY CHAIN

Ever Wonder What Running A $50B Capital Facilities Project Feels Like?

Eli Lilly and Company's expansion projects in the U.S. include greenfield sites where little infrastructure exists. Here's how the company is approaching the challenge.

Optimizing Packaging Systems For Reliable Drug Substance Transport

Learn how to develop robust packaging systems and understand why a secure, reliable supply chain is fundamental for the safe transport of critical drug substances and finished products globally.

A Practical Guide To Choosing The Right Cold Storage Solutions

Cold storage units like refrigerators, freezers, and ULT freezers are vital to scientific progress, preserving sensitive materials and supporting breakthroughs in developing cell and gene therapies.

FOCUS ON CLINICAL TRIALS

Assess The Success Of CRISPR Gene Therapies Using ddPCR Technology

Achieve high-fidelity results in gene therapy research. See how absolute quantification overcomes traditional limitations to provide the precision needed for validating CRISPR edits.

Tailoring An Approach To Support Bladder Cancer Breakthrough

Explore how a flexible operational strategy and expert site management help bladder cancer programs overcome complex logistical hurdles and achieve critical regulatory milestones.

Slow The Burn: How To Make Risk-Resilient Vendor Choices

Uncover how to identify common CRO selection pitfalls and apply expert-backed strategies to protect your clinical program from costly risks and delays.

21% Of CGT Clinical Holds Stem From CMC Issues. What Does This Tell Us?

Cell and gene therapy trials account for nearly 40% of all clinical holds reported by the NIH, with over 21% caused by CMC issues, often delaying approvals by over 6 months.

How Intelligent Automation Transforms Vendor Selection

Calculate how your small biotech can achieve faster timelines, improved cost control, and more strategic, transparent choices with a platform leveraging intelligent automation.

Inside The Payer Perspective On Cell And Gene Therapy Coverage

Find out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.

How The Cell And Gene Therapy Market Is Taking Shape

Targeting diseases at their genetic root, cell and gene therapies offer unprecedented hope. Yet, the industry grapples with balancing groundbreaking potential against the challenge of high-priced treatments.

CLINICAL TRIALS SOLUTIONS

DCT Solutions That Successfully Deliver Results - MRN - Medical Research Network

Connect With Cell & Gene: